Sarcopenia is associated with higher toxicity and poor prognosis of nasopharyngeal carcinoma

被引:37
作者
Hua, Xin [4 ]
Liao, Jun-Fang [5 ,6 ]
Huang, Xin [4 ]
Huang, Han-Ying [4 ]
Wen, Wen [4 ]
Long, Zhi-Qing [4 ]
Guo, Ling [3 ]
Yuan, Zhong-Yu [2 ]
Lin, Huan-Xin [1 ]
机构
[1] SunYat Sen Univ, Canc Ctr, Dept Radiotherapy, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China
[3] Sun Yat Sen Univ, Canc Ctr, Dept Nasopharyngeal Carcinoma, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China
[4] Sun Yat Sen Univ, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China
[5] Chinese Acad Med Sci & Peking Union Med Coll, Dept Radiat Oncol, Natl Canc Ctr, Canc Hosp,Natl Clin Res Ctr Canc, Shenzhen, Peoples R China
[6] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China
基金
中国国家自然科学基金;
关键词
concurrent chemoradiotherapy; nasopharyngeal carcinoma; sarcopenia; survival; toxicity; treatment response; SKELETAL-MUSCLE MASS; BODY-COMPOSITION; SOLID TUMORS; CHEMOTHERAPY; HEAD; RADIOTHERAPY; SURVIVAL; METAANALYSIS; EFFICACY;
D O I
10.1177/1758835920947612
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Given the growing evidence that sarcopenia is associated with toxicity and survival in various cancers, we investigated its significance in patients with nasopharyngeal carcinoma (NPC) receiving concurrent chemoradiotherapy (CCRT). Methods: In this retrospective analysis, we studied 862 NPC patients who had received CCRT between 2010 and 2014. Sarcopenia was determined using routine pre-radiotherapy computed tomography (CT) simulation scans at the third cervical vertebral level. Receiver-operating characteristic curve analyses were used to determine the optimal cutoff values. Propensity score matching (PSM) was applied to develop comparable cohorts of patients with or without sarcopenia. Results: A total of 862 patients were included as the primary cohort, and 308 patients were matched and regarded as the matched cohort. In the primary cohort, the 5-year overall survival (OS), locoregional recurrence-free survival, and distant metastasis-free survival (DMFS) rates for the sarcopenia groupversusnon-sarcopenia group were 78.2%versus93.6% (p < 0.001), 89.4%versus87.9% (p = 0.918), and 82.5%versus89.0% (p = 0.007), respectively. Univariate and multivariate survival analyses revealed that sarcopenia was an independent predictor of OS (p < 0.001 andp < 0.001) and DMFS (p = 0.009,p = 0.034). Patients with sarcopenia experienced significantly higher rates of treatment-related toxicities compared with patients without sarcopenia (p = 0.032). In addition, patients with sarcopenia also experienced significantly worse treatment response than those without sarcopenia (p = 0.004). Similar results were found in a PSM cohort. Conclusion: The current findings support that sarcopenia is a promising indicator for predicting clinical outcomes in NPC patients receiving CCRT. A simple and rapid analysis on CT simulation images can provide information about the therapeutic toxicity and survival prognosis, consequently guiding personalized multi-modality interventions during CCRT.
引用
收藏
页数:12
相关论文
共 34 条
[1]   Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy [J].
Bozzetti, F. .
ANNALS OF ONCOLOGY, 2017, 28 (09) :2107-2118
[2]   Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer [J].
Chemama, Stephanie ;
Bayar, Mohamed Amine ;
Lanoy, Emilie ;
Ammari, Samy ;
Stoclin, Annabelle ;
Goere, Diane ;
Elias, Dominique ;
Raynard, Bruno ;
Antoun, Sami .
ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (12) :3891-3898
[3]   Cancer Statistics in China, 2015 [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Baade, Peter D. ;
Zhang, Siwei ;
Zeng, Hongmei ;
Bray, Freddie ;
Jemal, Ahmedin ;
Yu, Xue Qin ;
He, Jie .
CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132
[4]   Nasopharyngeal carcinoma [J].
Chen, Yu-Pei ;
Chan, Anthony T. C. ;
Quynh-Thu Le ;
Blanchard, Pierre ;
Sun, Ying ;
Ma, Jun .
LANCET, 2019, 394 (10192) :64-80
[5]   Prognostic Significance of Sarcopenia With Inflammation in Patients With Head and Neck Cancer Who Underwent Definitive Chemoradiotherapy [J].
Cho, Yeona ;
Kim, Jun Won ;
Keum, Ki Chang ;
Lee, Chang Geol ;
Jeung, Hei Cheul ;
Lee, Ik Jae .
FRONTIERS IN ONCOLOGY, 2018, 8
[6]   Low skeletal muscle is associated with toxicity in patients included in phase I trials [J].
Cousin, Sophie ;
Hollebecque, A. ;
Koscielny, S. ;
Mir, O. ;
Varga, A. ;
Baracos, V. E. ;
Soria, J. C. ;
Antoun, S. .
INVESTIGATIONAL NEW DRUGS, 2014, 32 (02) :382-387
[7]   Sarcopenia: revised European consensus on definition and diagnosis [J].
Cruz-Jentoft, Alfonso J. ;
Bahat, Gulistan ;
Bauer, Juergen ;
Boirie, Yves ;
Bruyere, Olivier ;
Cederholm, Tommy ;
Cooper, Cyrus ;
Landi, Francesco ;
Rolland, Yves ;
Sayer, Avan Aihie ;
Schneider, Stephane M. ;
Sieber, Cornel C. ;
Topinkova, Eva ;
Vandewoude, Maurits ;
Visser, Marjolein ;
Zamboni, Mauro .
AGE AND AGEING, 2019, 48 (01) :16-31
[8]   Sarcopenia: European consensus on definition and diagnosis [J].
Cruz-Jentoft, Alfonso J. ;
Baeyens, Jean Pierre ;
Bauer, Juergen M. ;
Boirie, Yves ;
Cederholm, Tommy ;
Landi, Francesco ;
Martin, Finbarr C. ;
Michel, Jean-Pierre ;
Rolland, Yves ;
Schneider, Stephane M. ;
Topinkova, Eva ;
Vandewoude, Maurits ;
Zamboni, Mauro .
AGE AND AGEING, 2010, 39 (04) :412-423
[9]   Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy [J].
Dijksterhuis, Willemieke P. M. ;
Pruijt, Maarten J. ;
van der Woude, Stephanie O. ;
Klaassen, Remy ;
Kurk, Sophie A. ;
van Oijen, Martijn G. H. ;
van Laarhoven, Hanneke W. M. .
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2019, 10 (01) :199-206
[10]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247